The Effect of Bevacizumab Therapy on Reducing Erythrocyte Transfusion Requirements and Preventing Iron Deficiency in Patients With Hereditary Hemorrhagic Telangiectasia

Key Points

• Bevacizumab therapy significantly reduces erythrocyte transfusion requirements, improving patient outcomes.
• Statistical analysis revealed notable improvements in iron parameters over the treatment period.
• Observational analysis across multiple centers measured the impact of IV bevacizumab on HHT-related bleeding.
• This finding supports the effectiveness of bevacizumab for managing transfusion needs and iron deficiency.

Abstract